Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists

被引:61
作者
Keenan, RM
Callahan, JF
Samanen, JM
Bondinell, WE
Calvo, RR
Chen, LC
DeBrosse, C
Eggleston, DS
Haltiwanger, RC
Hwang, SM
Jakas, DR
Ku, TW
Miller, WH
Newlander, KA
Nichols, A
Parker, MF
Southhall, LS
Uzinskas, I
Vasko-Moser, JA
Venslavsky, JW
Wong, AS
Huffman, WF
机构
[1] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Med Chem, Collegeville, PA 19426 USA
[2] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Cellular Biochem, Collegeville, PA 19426 USA
[3] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Cardiovasc Pharmacol, Collegeville, PA 19426 USA
[4] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Analyt Chem, Collegeville, PA 19426 USA
[5] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Phys & Struct Chem, Collegeville, PA 19426 USA
关键词
D O I
10.1021/jm980166z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previously, we reported the direct design of highly potent nonpeptide 3-oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides were the exocyclic amide at the 8-position which overlaid the Arg carbonyl, the phenyl ring which maintained an extended Gly conformation, and the diazepine ring which mimicked the gamma-turn at Asp. In this paper, we investigate conformational preferences of the 8-substituted benzodiazepine analogues by examining structural modifications to both the exocyclic amide and the seven-membered diazepine ring and by studying the conformation of the benzodiazepine ring using molecular modeling, X-ray crystallography, and NMR. We found that the directionality of the amide at the 8-position had little effect on activity and the (E)-olefin analogue retained significant potency, indicating that the trans orientation of the amide, and not the carbonyl or NH groups, made the largest contribution to the observed activity. For the diazepine ring, with the exception of the closely analogous 3-oxo-2-benzazepine ring system described previously, all of the modifications led to a significant reduction in activity compared to the potent 3-oxo-1,4-benzodiazepine parent ring system, implicating this particular type of ring system as a desirable structural feature for high potency. Energy minimizations of a number of the modified analogues revealed that none could adopt the same low-energy conformation as the one shared by the active (S)-isomer of the 3-oxo-1,4-benzodiazepines and 3-oxo-2-benzazepines. The overall data suggest that the features contributing to the observed high potency in this series are the orientation of the 3-4 amide and the conformational constraint imposed by the seven-membered ring, both of which position the key acidic acid basic groups in the proper spatial relationship.
引用
收藏
页码:545 / 559
页数:15
相关论文
共 36 条
[1]   CONFORMATIONALLY CONSTRAINED PEPTIDES AND SEMIPEPTIDES DERIVED FROM RGD AS POTENT INHIBITORS OF THE PLATELET FIBRINOGEN RECEPTOR AND PLATELET-AGGREGATION [J].
ALI, FE ;
BENNETT, DB ;
CALVO, RR ;
ELLIOTT, JD ;
HWANG, SM ;
KU, TW ;
LAGO, MA ;
NICHOLS, AJ ;
ROMOFF, TT ;
SHAH, DH ;
VASKO, JA ;
WONG, AS ;
YELLIN, TO ;
YUAN, CK ;
SAMANEN, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (06) :769-780
[2]   STRUCTURAL STUDIES OF A FAMILY OF HIGH-AFFINITY LIGANDS FOR GPIIB/IIIA [J].
BACH, AC ;
EYERMANN, CJ ;
GROSS, JD ;
BOWER, MJ ;
HARLOW, RL ;
WEBER, PC ;
DEGRADO, WF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (08) :3207-3219
[3]   CYCLIC RGD PEPTIDE ANALOGS AS ANTIPLATELET ANTITHROMBOTICS [J].
BARKER, PL ;
BULLENS, S ;
BUNTING, S ;
BURDICK, DJ ;
CHAN, KS ;
DEISHER, T ;
EIGENBROT, C ;
GADEK, TR ;
GANTZOS, R ;
LIPARI, MT ;
MUIR, CD ;
NAPIER, MA ;
PITTI, RM ;
PADUA, A ;
QUAN, C ;
STANLEY, M ;
STRUBLE, M ;
TOM, JYK ;
BURNIER, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) :2040-2048
[4]   From peptide to non-peptide .3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus [J].
Blackburn, BK ;
Lee, A ;
Baier, M ;
Kohl, B ;
Olivero, AG ;
Matamoros, R ;
Robarge, KD ;
McDowell, RS .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (05) :717-729
[5]  
Bondinell W E, 1994, Bioorg Med Chem, V2, P897, DOI 10.1016/S0968-0896(00)82039-8
[6]  
BONDINELL WE, UNPUB
[7]  
BONDINELL WE, 1994, Patent No. 9414776
[8]   DESIGN AND SYNTHESIS OF A C-7 MIMETIC FOR THE PREDICTED GAMMA-TURN CONFORMATION FOUND IN SEVERAL CONSTRAINED RGD ANTAGONISTS [J].
CALLAHAN, JF ;
BEAN, JW ;
BURGESS, JL ;
EGGLESTON, DS ;
HWANG, SM ;
KOPPLE, KD ;
KOSTER, PF ;
NICHOLS, A ;
PEISHOFF, CE ;
SAMANEN, JM ;
VASKO, JA ;
WONG, A ;
HUFFMAN, WF .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (21) :3970-3972
[9]   DESIGN AND SYNTHESIS OF NOVEL CYCLIC RGD-CONTAINING PEPTIDES AS HIGHLY POTENT AND SELECTIVE INTEGRIN ALPHA(IIB)BETA(3) ANTAGONISTS [J].
CHENG, S ;
CRAIG, WS ;
MULLEN, D ;
TSCHOPP, JF ;
DIXON, D ;
PIERSCHBACHER, MD .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (01) :1-8
[10]  
COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302